Abstract
Aim
To establish a relationship between the level of uric acid and the risk of development of type 2 diabetes mellitus (DM2) on the FINDRISC scale in women of moderate and high cardiovascular risk.
Material and methods
103 women (average age (58,39±11,09) years) with moderate and high cardiovascular risk were examined. Women were divided into groups depending on age: 1 group of age to 50 years old, 2 groups with the age of 50–60 years old, 3 groups more than 60 years. The risk of developing the DM2 in the next 10 years was evaluated using the FINDRISC questionnaire. The level of uric acid was determined by a photometric substantial method. For statistical analysis, SPSSIBM, version 19.0.
Results
It has been established that women, in general, had an increased risk of developing DM2 (11,0 [7,0–14,0] points). The level of uric acid in them was (295,0 [230,0–380,5] μmol/l). In the distribution of women by age, there was no probable difference in uric acid levels (257,0 [249,0–257,5]; 256,0 [210,7–353,3]; 295,0 [231,0–362,5] μmol/l; p>0,05). However, the risk of developing DM2 has probably grown in women depending on age (4,00 [0,25–9,25]; 9,50 [7,00–14,00]; 14,50 [12,50–16,00] points). Uric acid correlated with the FINDRISC scale at the significance level (0,489, p=0,05). However, with the distribution of women, depending on age, we observed the interconnection of uric acid with the risk of developing DM2 at the level of significance only in women 2 groups (0,604, p=0,01).
Conclusions
The level of uric acid is interacting with the risk of developing DM2 on the FINDRISC scale in women of moderate and high cardiovascular risk at the age of 50–60 years.
FUNDunding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”, Department of Chronic Non-communicable Disease Prevention
Letter by Tampaki et al Regarding Article, “Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk”
